Lv7
3214 积分 2021-10-12 加入
Interim safety and clinical activity of nivolumab (Nivo) in combination with S-1/capecitabine plus oxaliplatin in patients (pts) with previously untreated unresectable advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: part 1 study of ATTRACTION-04 (ONO-4538-37)
8天前
已完结
基于真实世界数据的胃癌肝转移全国多中心回顾性队列研究（RECORD研究）年度报告
14天前
已完结
First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer: The GEMSTONE-303 Randomized Clinical Trial
15天前
已关闭
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial
19天前
已关闭
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial
19天前
已完结
WHO groups cancer together with chronic diseases
22天前
已关闭
[Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer for patients (2024 edition)]
23天前
已完结
Faricimab Treat-and-Extend for Diabetic Macular Edema
1个月前
已完结
Visual Outcomes Associated With Patterns of Macular Edema Resolution in Central Retinal Vein Occlusion Treated With Anti–Vascular Endothelial Growth Factor Therapy
1个月前
已完结
Second-Line Treatment with Axitinib Plus Toripalimab in Metastatic Renal Cell Carcinoma: A Retrospective Multicenter Study
1个月前
已完结
皖公网安备34019202002308
